Nicotinic Acetylcholine Receptor beta 2/CHRNB2 Double Nickase Plasmid (h): sc-401641-NIC
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- Nicotinic Acetylcholine Receptor beta 2/CHRNB2 Double Nickase Plasmid (h) consists of a pair of plasmids each encoding a D10A mutated Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed to knockout gene expression with greater specificity than its CRISPR/Cas9 KO counterpart
- Paired gRNA sequences are offset by approximately 20 bp to allow for specific Cas9-mediated double nicking of the genomic DNA, which mimics a DSB
- One plasmid in the pair contains a puromycin-resistance gene for selection; the other plasmid in the pair contains a GFP marker to visually confirm transfection
- Nicotinic Acetylcholine Receptor beta 2/CHRNB2 Double Nickase Plasmid (h) and Nicotinic Acetylcholine Receptor beta 2/CHRNB2 Double Nickase Plasmid (h2) encode distinct paired gRNA designs targeting CHRNB2. One or both designs may be available
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: Nicotinic Acetylcholine Receptor beta 2/CHRNB2 Antibody (270): sc-58596
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Nicotinic Acetylcholine Receptor beta 2/CHRNB2 Double Nickase Plasmid (h) | sc-401641-NIC | 20 µg | $410.00 | |||
Nicotinic Acetylcholine Receptor beta 2/CHRNB2 Double Nickase Plasmid (h2) | sc-401641-NIC-2 | 20 µg | $410.00 |
CHRNB2 encodes the β2 subunit of neuronal nicotinic acetylcholine receptors, ligand-gated ion channels that assemble as heteropentimers with other nAChR subunits to mediate fast synaptic transmission. Upon acetylcholine or nicotine binding, β2-containing receptors conduct cations, elevating intracellular Na⁺ and Ca²⁺ and coupling to activity-dependent signaling networks that shape excitability, neurotransmitter release, and synaptic plasticity. This cholinergic signaling intersects with pathways regulating calcium homeostasis, MAPK/ERK signaling, and dopaminergic circuit function. Genetic variation or altered expression of CHRNB2 has been linked to neuropsychiatric and neurodevelopmental phenotypes, and it is also studied in the context of nicotine dependence and seizure-related disorders.
Nicotinic Acetylcholine Receptor beta 2/CHRNB2 Double Nickase Plasmid (h) consists of a matched pair of plasmids engineered for high-specificity editing of the CHRNB2 locus in human cell lines. Each plasmid expresses a Cas9 D10A nickase and a distinct sgRNA targeting opposite DNA strands within CHRNB2. When directed to adjacent sites on opposite DNA strands, the two nickases generate offset single-strand nicks that together produce a staggered double-strand break, requiring coordinated on-target activity from both guides. The resulting DNA break is resolved by endogenous cellular repair pathways, most commonly through non-homologous end joining (NHEJ), leading to insertions or deletions that disrupt CHRNB2 function. By requiring dual sgRNA engagement at the target locus, the double nicking approach enhances editing specificity and provides a complementary CRISPR strategy for applications where additional control over targeting precision is desired.
To support efficient identification of edited cells, one plasmid encodes GFP for fluorescent visualization of transfected populations, while the companion plasmid carries a puromycin resistance gene for antibiotic selection. Together, these features support efficient enrichment of co-transfected populations and simplify the validation of CHRNB2-disrupted clones.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.